The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases
Open accessAbstract
Pseudomonas aeruginosa (P. aeruginosa) is a ubiquitous and opportunistic microorganism and is considered one of the most significant pathogens that produce chronic colonization and infection of the lower respiratory tract, especially in people with chronic inflammatory airway diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and bronchiectasis. From a microbiological viewpoint, the presence and persistence of P. aeruginosa over time are characterized by adaptation within the host that precludes any rapid, devastating injury to the host. Moreover, this microorganism usually develops antibiotic resistance, which is accelerated in chronic infections especially in those situations where the frequent use of antimicrobials facilitates the selection of “hypermutator P. aeruginosa strain”. This phenomenon has been observed in people with bronchiectasis, CF, and the “exacerbator” COPD phenotype. From a clinical point of view, a chronic bronchial infection of P. aeruginosa has been related to more severity and poor prognosis in people with CF, bronchiectasis, and probably in COPD, but little is known on the effect of this microorganism infection in people with asthma. The relationship between the impact and treatment of P. aeruginosa infection in people with airway diseases emerges as an important future challenge and it is the most important objective of this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pseudomonas aeruginosa : new insights into pathogenesis and host defenses
Gellatly, S. L., & Hancock, R. E. W. (2013) · Pathogens and Disease · doi:10.1111/2049-632x.12033 · Cited by 1,295 · cited 1×
“aeruginosa over time are characterized by adaptation within the host, followed by a reduced susceptibility to bacterial invasion (albeit with a consolidation of the bacterial presence) that precludes any rapid, devastating injury to the host [12].”
BackgroundThe bronchiectasis severity index. An international derivation and validation study
Chalmers, J. D., Goeminne, P., Aliberti, S., McDonnell, M. J., Lonni, S., Davidson, J., Poppelwell, L., Salih, W., Pesci, A., Dupont, L. J., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1575oc · Cited by 1,093 · cited 6×
“The importance of CBI by P. aeruginosa for prognosis has been reflected in the three multidimensional scores that have been validated to assess the severity of bronchiectasis and predict both exacerbations and mortality: the FACED [131], E-FACED [148], and BSI [144].”
BackgroundInfluentialMultidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score
Martínez-García, M. Á., de Gracia, J., Vendrell Relat, M., Girón, R.-M., Máiz Carro, L., de la Rosa Carrillo, D., & Olveira, C. (2014) · European Respiratory Journal · doi:10.1183/09031936.00026313 · Cited by 503
Self-citationFauvart, M., De Groote, V. N., & Michiels, J. (2011) · Journal of Medical Microbiology · doi:10.1099/jmm.0.030932-0 · Cited by 425 · cited 1×
“aeruginosa [13,94,95], achieves high rates of eradication and delays CBI.”
BackgroundQuittner, A. L., Modi, A. C., Wainwright, C., Otto, K., Kirihara, J., & Montgomery, A. B. (2009) · Chest · doi:10.1378/chest.08-1190 · Cited by 400
Inflammation and Airway Microbiota during Cystic Fibrosis Pulmonary Exacerbations
Zemanick, E. T., Harris, J. K., Wagner, B. D., Robertson, C. E., Sagel, S. D., Stevens, M. J., Accurso, F. J., & Laguna, T. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062917 · Cited by 180 · cited 2×
“It is associated with more respiratory symptoms [27,80], a greater number of exacerbations [49,50,61,62,81], increased inflammation (with higher concentrations of neutrophil elastase in the sputum), higher levels of serum C reactive protein (CRP) [54], and reduced monocyte response to various stimuli [51].”
BackgroundSawicki, G. S., Rasouliyan, L., McMullen, A. H., Wagener, J. S., McColley, S. A., Pasta, D. J., & Quittner, A. L. (2011) · Pediatric Pulmonology · doi:10.1002/ppul.21325 · Cited by 106
Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis
Smith, S., Rowbotham, N. J., & Regan, K. H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001021.pub3 · Cited by 92 · cited 1×
“Furthermore, the most recent Cochrane review [125] observed improvements after the administration of liposomal amikacin, primarily in the number of exacerbations and the lung function.”
Background
Cited by
Elfadadny, A., Ragab, R. F., AlHarbi, M., Badshah, F., Ibáñez-Arancibia, E., Farag, A., Hendawy, A. O., De los Ríos-Escalante, P. R., Aboubakr, M., Zakai, S. A., et al. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1374466 · Cited by 340
Metadata
- Authors
- Garcia-Clemente, M., de la Rosa, D., Máiz, L., Girón, R., Blanco, M., Olveira, C., Canton, R., & Martinez-García, M. A.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-11-24
- Volume
- 9
- Issue
- 12
- Pages
- 3800
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W3107577893
- Cited by
- 160
- References
- 8
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.